NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR WITHIN
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF
15 October 2024
IXICO PLC
("IXICO" or the "Company")
Result of Retail Offer
Further to the announcement dated 8 October 2024, IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience, is pleased to announce that, following the closing of the Retail Offer on the BookBuild platform on 14 October 2024, 516,244 New Ordinary Shares will be issued at the Issue Price of
Consequently, conditional on the passing of the Resolutions at the General Meeting, 41,315,792 Placing Shares, 789,472 Subscription Shares and 516,244 Retail Offer Shares, resulting in a total of 42,621,508 new Ordinary Shares, will be issued in relation to the Fundraising, raising total gross proceeds of
Admission and Total Voting Rights
Application has been made for the Retail Offer Shares to be admitted to trading on AIM ("Admission"). Admission is expected to take place at 8.00 a.m. on or around 28 October 2024.
The Retail Offer Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with existing Ordinary Shares including the right to receive all dividends and other distributions declared, made or paid after their date of issue.
Following Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 92,668,598 with each Ordinary Share carrying the right to one vote. There are no shares held in treasury and therefore, following Admission, the total number of voting rights in the Company will be 92,668,598. The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure, Guidance and Transparency Rules.
For the purposes of
Capitalised terms used in this announcement have the meaning given to them in the Placing and Retail Offer announcement dated 8 October 2024, unless otherwise defined in this announcement.
For further information please contact:
|
IXICO plc |
+44 (0) 20 3763 7499 |
|
Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer |
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated adviser and sole broker) |
+44 (0) 20 7220 0500 |
|
Giles Balleny / Dan Hodkinson (Corporate Finance) |
|
|
Nigel Birks (Life Sciences Specialist Sales) |
|
|
Harriet Ward (Corporate Broking) |
|
|
Michael F Johnson / Tamar Cranford Smith (Sales) |
|
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on X (formerly Twitter) @IXICOnews
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.